Skip to Content

PharmaCyte Biotech Inc PMCB

Morningstar Rating
$2.10 +0.01 (0.48%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

PMCB is trading at a 378% premium.
Price
$2.12
Fair Value
$7.18
Uncertainty
Extreme
1-Star Price
$57.53
5-Star Price
$9.64
Economic Moat
Wckf
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PMCB is a good fit for your portfolio.

Trading Information

Previous Close Price
$2.09
Day Range
$2.062.16
52-Week Range
$1.923.23
Bid/Ask
$2.05 / $2.45
Market Cap
$17.75 Mil
Volume/Avg
3,176 / 24,698

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
176.48%

Company Profile

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
2

Valuation

Metric
PMCB
Price/Earnings (Normalized)
Price/Book Value
0.57
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
PMCB
Quick Ratio
8.12
Current Ratio
8.16
Interest Coverage
Quick Ratio
PMCB

Profitability

Metric
PMCB
Return on Assets (Normalized)
−0.61%
Return on Equity (Normalized)
−0.89%
Return on Invested Capital (Normalized)
−6.07%
Return on Assets
PMCB
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRRfglygpskpGyt$586.1 Bil
VRTX
Vertex Pharmaceuticals IncBnzwpcgyPyjrpy$113.7 Bil
REGN
Regeneron Pharmaceuticals IncGrjwdfmgJrdlwy$108.2 Bil
MRNA
Moderna IncQswxvgdrnVkxj$50.9 Bil
ARGX
argenx SE ADRGwvlbndmNswy$22.0 Bil
BNTX
BioNTech SE ADRXshnhyyxWynv$21.8 Bil
ALNY
Alnylam Pharmaceuticals IncCktxcgnyyDhdsmh$18.9 Bil
BMRN
Biomarin Pharmaceutical IncRfkcsyjqcRdvxf$14.6 Bil
INCY
Incyte CorpKbgnghkwsGmsvry$12.8 Bil
RPRX
Royalty Pharma PLC Class ANpxztyjrpKxbhzk$12.3 Bil

Sponsor Center